POST Online Media Lite Edition



 

Horizon Discovery signs development agreement with Ventanta

Staff Writer |
Gene editing technologies company Horizon Discovery Group has entered into a co-development and commercialisation agreement with Ventana Medical Systems, a member of the Roche Group.

Article continues below






The AIM-traded firm said the agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards in cancer tissue diagnostics to support the development and validation of IHC assays.

Its board described Ventana as a "global leader in tissue diagnostics" including immunohistochemistry, providing products used in clinical histology and drug development research laboratories.

To support the development and validation of IHC assays, Ventana has partnered with Horizon as a provider of highly characterised 'Reference Standards'.

Under the terms of the agreement, Ventana has the option to commission projects from Horizon, whereupon Horizon will develop the applicable cell lines and the associated derivative Reference Standard materials.

Horizon will retain primary responsibility for commercialising the Reference Standards and will serve as the primary distribution channel to end-customers in the tissue diagnostics market, providing the company with additional ongoing revenue streams.

Ventana will hold the option to co-distribute any developed Reference Standards.


What to read next

Horizon Discovery inks subscription-based licensing deal
Horizon Lines to be acquired by Matson for $0.72
Horizon Discovery expects 7% better results